CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung NaingFiona ThistlethwaiteElisabeth G E De VriesFerry A L M EskensNataliya UbohaPatrick A OttPatricia LoRussoJavier Garcia-CorbachoValentina BoniJohanna BendellKaren A AutioManreet RandhawaGreg DurmMarta Gil-MartinMark StrohAlison L HannahHendrik-Tobias ArkenauAlexander I SpiraPublished in: Journal for immunotherapy of cancer (2022)
NCT03013491.